John Leonard, Intellia CEO
September 16, 2022 11:35 AM EDT
R&D

Along­side promis­ing first HAE da­ta, In­tel­lia posts read­out in Re­gen­eron-part­nered AT­TR pro­gram

Lei Lei Wu

News Reporter

In Au­gust, Al­ny­lam tout­ed a Phase III suc­cess for transthyretin amy­loi­do­sis, or AT­TR for short, with car­diomy­opa­thy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times